BioNexus Gene Lab Corp Quarterly Debt-to-equity in % from Q3 2019 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
BioNexus Gene Lab Corp quarterly Debt-to-equity history and growth rate from Q3 2019 to Q2 2024.
  • BioNexus Gene Lab Corp Debt-to-equity for the quarter ending June 30, 2024 was 18.1 %, a 35.7% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 18.1 -10.1 -35.7% Jun 30, 2024
Q1 2024 21.2 -4.18 -16.5% Mar 31, 2024
Q4 2023 22.8 -3.29 -12.6% Dec 31, 2023
Q3 2023 26.4 -0.36 -1.35% Sep 30, 2023
Q2 2023 28.2 -2.67 -8.65% Jun 30, 2023
Q1 2023 25.4 -9.36 -26.9% Mar 31, 2023
Q4 2022 26.1 -12.9 -33.2% Dec 31, 2022
Q3 2022 26.7 -16.9 -38.7% Sep 30, 2022
Q2 2022 30.9 -3.54 -10.3% Jun 30, 2022
Q1 2022 34.8 +9.19 +36% Mar 31, 2022
Q4 2021 39 +24.5 +170% Dec 31, 2021
Q3 2021 43.6 +41.7 +2246% Sep 30, 2021
Q2 2021 34.4 +31.9 +1259% Jun 30, 2021
Q1 2021 25.6 +21.5 +526% Mar 31, 2021
Q4 2020 14.5 +6.03 +71.6% Dec 31, 2020
Q3 2020 1.86 -6.35 -77.4% Sep 30, 2020
Q2 2020 2.53 Jun 30, 2020
Q1 2020 4.08 Mar 31, 2020
Q4 2019 8.42 Dec 31, 2019
Q3 2019 8.2 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.